Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

144 results about "Polylactide co glycolide" patented technology

Polyester poly(DL-lactide-co-glycolide) (PLGA) is a copolymer of poly lactic acid (PLA) and poly glycolic acid (PGA). Poly lactic acid contains an asymmetric α-carbon which is typically described as the D or L form in classical stereochemical terms and sometimes as R and S form, respectively.

Sustained intraocular delivery of drugs from biodegradable polymeric microparticles

Biodegradable polymeric microparticle compositions containing one or more active agents, especially those useful for treating or preventing or one or more diseases or disorders of the eye, and methods of making and using thereof, are described. The microsphere compositions release an effective amount of the one or more active agents for a period greater than 14 days in vivo, preferably greater than 60 days in vivo, more preferably up to 73 days in vivo, more preferably greater than 90 days in vivo, even more preferably over 100 days in vivo, and most preferably greater than 107 days in vivo. In a preferred embodiment, the microparticle compositions contain one or more active agents useful for managing elevated intraocular pressure (TOP) in the eye. In one embodiment, the microspheres are formed from polylactide-co-glycolide (“PLGA”); in another embodiment, the microspheres are formed from a blend PLGA and poly lactic acid (“PLA”). Relatively hydrophilic, and preferably carboxylated, polymeric materials such as PLGA are used for a drug such as timolol maleate, which is relatively water soluble, to increase drug loading. Higher molecular weight polymers, as well as the ratio of LA (which has a longer degradation time, up to one to two years) to GA (which has a short degradation time, as short as a few days to a week), are used to provide release over a longer period of time. The combination of drug loading and release rate, as well as the minimization of initial burst release, result in prolonged release of a higher amount of drug.
Owner:YALE UNIV +1

Sustained-release micro-spheres preparation containing recombined erythropoietin and preparation method and use thereof

The invention discloses a slow-release microsphere preparation containing a recombined human haemopoietin. The slow-release microsphere preparation is prepared by the S/O/W compound emulsion solvent volatilization method. The preparation method comprises that: firstly, by the freeze-drying method, a micro particle containing the human serum albumin and the recombined human haemopoietin is prepared; secondly, by using a biodegradable high molecular material of lactic acid-glycollic acid block copolymer as a carrier material, the micro particle containing the human serum albumin and the recombined human haemopoietin is encapsulated; and thirdly, the lactic acid-glycollic acid block copolymer slow-release microsphere preparation containing the recombined human haemopoietin is prepared. The microsphere of the invention has the advantages of smooth surface, uniform appearance, regular size and no adhesion, the average particle size is between 70 and 105mu m; moreover, the microsphere is high in drug-carrying quantity and encapsulating rate, and the in vitro slow release period is more than 30 days. The obtained slow-release microsphere preparation is good in biocompatibility and can be used for non-intravenous drug administration such as hypodermic drug administration and intramuscular drug administration, and when used as a drug preparation for treating renal anemia, the slow-release microsphere preparation can improve the hematocrit of a patient.
Owner:HEBEI NORMAL UNIV

Absorbable intraosseous fixing device with biological activity and plasticity and forming method

The invention relates to the field of biological medical apparatus and instruments, and particularly relates to an absorbable intraosseous fixing device with biological activity and plasticity and a forming method. The absorbable intraosseous fixing device comprises a bone fracture plate and bone screws, wherein the bone fracture plate is provided with fixing holes and is made by a biologically absorbable high polymer material and biologically active ceramics or biologically active glass; the biologically absorbable high polymer material is 70-95% of the total weight of a composite material in parts by weight, and the biologically active ceramics or biologically active glass takes up 5-30% of the total weight of the composite material; the biologically absorbable high polymer material is selected from one or more of polylactic acid, polycaprolactone, polylactic acid-glycolic acid copolymer, polyglycolic acid, polyhydroxyalkanoate and polyhydroxybutyrate, and the molecular weight is 100,000 to 2,000,000. The absorbable intraosseous fixing device is good in biocompatibility, and can be degraded after the device is implanted in the body; meanwhile, aseptic inflammation caused in the course of material degradation can be reduced, and the pain of a patient can be alleviated; in addition, the personalized customization can be realized.
Owner:深圳市博立生物材料有限公司

Mesoporous bioactive glass/polylactic acid-glycolic acid copolymer composite microspheres and preparation method and application thereof

The invention discloses mesoporous bioactive glass / poly(lactic-co-glycolic acid) (PLGA) composite microspheres and a preparation method and application thereof. The mesoporous bioactive glass / poly(lactic-co-glycolic acid) (PLGA) composite microspheres are prepared by the following method of: firstly, preparing mesoporous bioactive glass by using a microemulsion technology in combination with a sol-gel template method, then sequentially adding PLGA, span 80 and the mesoporous bioactive glass into dichloromethane, and carrying out uniform stirring and ultrasonic dispersing to form S / O emulsion;and sequentially adding the S / O emulsion into prepared polyethylene solution W1 and W2 with different concentration, stirring to evaporate a solvent, and carrying out washing, centrifugation, and freeze-drying to obtain the product. The preparation process flow of the composite microspheres is easy to control, and due to the addition of the mesoporous bioactive glass, the bone induction capabilityand the drug loading and slow release capability of the composite microspheres are improved; and the composite microspheres have good application prospect in the fields of bone and tooth tissue repair, tissue engineering and slow release carriers such as drugs, proteins and genes and the like.
Owner:SOUTH CHINA UNIV OF TECH +1

Targeted polymer micelle magnetic nanoparticle, and preparation method and application thereof

InactiveCN104815341AImprove independent innovation capabilitiesSecurity Image ImagingEmulsion deliveryIn-vivo testing preparationsPancreas CancersPolyethylene glycol
The invention provides a polymer micelle magnetic nanoparticle having a selective specific targeting function on pancreas cancer. A preparation method of the polymer micelle magnetic nanoparticle comprises the following steps: carrying out an amide reaction on a carboxyl group on a CKAAKN polypeptide and an amino group on the carboxyl group on polyethylene glycol-polylactic acid-glycolic acid, coupling the CKAAKN polypeptide to prepare a CKAAKN-PEG-PLGA graft product, and carrying out an aqueous solvent diffusion technology with a Fe3O4 magnetic nanoparticle as a targeting marker material to prepare the polymer micelle magnetic nanoparticle. The preparation method has the advantages of reasonable design, convenient operation and low cost. The polymer micelle magnetic nanoparticle provided by the invention has high magnetic Fe3O4 nanoparticle wrapping ability, has the advantages of good stability and dispersibility, small particle size and uniform dispersion, can enhance the targeted uptake ability of the pancreas cancer to improve the uptake rate, and can be used as a pancreas cancer targeted magnetic resonance specific contrast agent to realize safe and rapid pancreas cancer targeted molecule image imaging.
Owner:ZHEJIANG UNIV

Controlled-release injection containing antidiuresis components and preparation method thereof

The invention relates to a controlled-release injection containing antidiuresis components and a preparation method thereof. The controlled-release injection contains main drugs of desmopressin acetate, sustained release auxiliary materials, suspending agent and menstruum. The sustained release auxiliary materials are selected from polylactic acid, polylactic acid-co-glycolic acid, ethylene-vinyl acetate copolymer, polifeprosan and the like, which can be used for slowly releasing medicine into disease local parts in a degrading and absorbing process, so that general toxicity reaction is obviously reduced, and simultaneously, the effective medicine concentration can be maintained on the disease local parts; the suspending agent is selected from sodium carboxymethylcellulose, mannitol and the like, which is used for suspending sustained-release granules or microspheres of biological active ingredients; and the menstruum is common menstruum or special menstruum containing the suspending agent, wherein the common menstruum is selected from distilled water, water for injection, physiological lotion, absolute ethyl alcohol or buffer solution prepared by various salts, and the like. According to the controlled-release injection, the action time of the medicine can be prolonged, the dosage times are reduced, the stability of blood drug concentration in vivo is maintained, and the drug toxic and side effects are reduced.
Owner:无锡市恒益健康科技有限公司

Water-based ink for printing PVC decorative material and preparation method thereof

The invention belongs to the technical field of water-based ink, and provides water-based ink for printing a PVC decorative material and a preparation method of the water-based ink. The invention discloses water-based ink for printing a PVC decorative material. The water-based ink comprises the following components in parts by weight: 45-50 parts of water-based color paste, 15-20 parts of water-based acrylate emulsion, 20-25 parts of water-based acrylic acid modified polyurethane emulsion, 1-2 parts of water-based wax paste, 3-5 parts of a pH stabilizer, 0.9-1.5 parts of an antifoaming agent,0.5-1 part of a leveling agent, 1-2 parts of a drier and 2-5 parts of deionized water. Wherein the water-based color paste is prepared from the following components in parts by weight: 40-60 parts ofwater and 1-5 parts of additive; 10 to 20 parts of water-based acrylic resin liquid; wherein the component A is prepared from, by mass, 33-35 parts of organic pigment, 2-4 parts of wetting dispersant,0.9-1.5 parts of organic silicon defoamer and 40-45 parts of deionized water, and the drier is a mixed solution of nano yttrium oxide, butadiene triethoxysilane, polylactic acid-glycolic acid copolymer and deionized water according to the mass ratio of 1: 0.2: 3: 7. By means of the technical scheme, the problems that in the prior art, water-based ink is slow in drying, low in adhesion fastness and poor in stability are solved.
Owner:石家庄市博思特油墨有限公司 +1

Controlled-release PLGA microsphere containing dexamethasone transforming growth factor and preparation method of controlled-release PLGA microsphere

The invention provides a controlled-release polylactic acid-glycolic acid copolymer microsphere containing a dexamethasone transforming growth factor. A preparation method comprises the following steps: preparing a DEX/PLGA composite microsphere by a water-oil-water emulsion process; positively charging the polylactic acid-glycolic acid copolymer microsphere embedded with DEX through polyethyleneimine of which the surface is covered with positive charges, and mixing TGF-beta3 with a heparin/poly L-lysine solution to form a mixture of which the molar charge ratio is 0-3.15; and mixing TGF-beta3-embedded heparin/poly L-lysine nanoparticles with the PLGA microsphere embedded with the DEX, and covering to obtain the microsphere. The growth-promoting proliferation differentiation action of the growth factor and the anti-inflammatory action of the DEX are compounded; the inflammatory effects caused by a cell attachment carrier are reduced; the controlled-release polylactic acid-glycolic acid copolymer microsphere relatively adapts to cell attachment; the controlled-release polylactic acid-glycolic acid copolymer microsphere is nontoxic and harmless to a living body; a cell scaffold can be degraded by the living body after being treated, and can be used as a carrier for preparing a biological scaffold.
Owner:ZHEJIANG UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products